Evofem Biosciences Inc 2026年季度报告

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ The number of shares of the registrant’s Common Stock, $0.0001 par value per share, outstanding as of May 11, 2026 was 132,530,081. Table of Contents FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q (Quarterly Report), contains forward-looking statements that involve substantial risks anduncertainties. The forward-looking statements are contained principally in the section entitled “Management’s Discussion and Analysis ofFinancial Condition and Results of Operations.” All statements, other than statements of historical facts, contained in this Quarterly Report,including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives ofmanagement, are forward-looking statements. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “contemplate,” “continue,” These forward-looking statements include, among other things, statements about: ●our ability to continue as a going concern;●our ability to remediate the material weaknesses in our internal controls and procedures identified by management;●our ability to obtain necessary approvals of any corporate action(s) needing stockholder or other approvals;●our ability to file Annual and Quarterly Reports on a timely basis;●our ability to raise additional capital to fund our operations if and as needed;●our ability to achieve and sustain profitability; ●our estimates regarding expenses, revenues, financial performance, and capital requirements, including the length of time our capitalresources will sustain our operations;●the Notices of Default and cancellation of Forbearance Agreement received from Future Pak, LLC and any potential legal action(s) againstthe Company related thereto, including that its assets that could be foreclosed upon and potential negative outcome(s) thereof;●our ability to comply with the provisions and requirements of our debt arrangements, to avoid future defaults pursuant to our debtarrangements, and to pay amounts owed, including any amounts that may be accelerated, pursuant to our debt arrangements;●our ability to successfully commercialize PHEXX®(lactic acid, citric acid and potassium bitartrate) vaginal gel (PHEXX) (formerly Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, wecaution you that these statements are based on our projections of the future which are subject to known and unknown risks and uncertaintiesand other factors that may cause our actual results, level of activity, performance, or achievements to differ from those expressed or implied bythese forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-lookingstatements, and you should not place undue reliance on our forward-looking statements. All forward-looking statements are qualified in theirentirety by this cautionary statement. Forward-looking statements should be regarded solely as our current plans, estimates and beliefs. Youshould read this Quarterly Report and the documents that we have filed as exhibits to this Quarterly Report and incorporated by reference This Quarterly Report contains estimates and other statistical data made by independent parties and by the Company relating to marketsize and growth and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give Unless the context requires otherwise, references in this Quarterly Report to “Evofem,” “Company,” “we,” “us” and “our” refer toEvofem Biosciences, Inc. and its subsidiaries. Biosciences, Inc. or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly Reportmay appear without the®, ™ or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do notintend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed toimply a relationship with, or endorsement or sponsorship of us by, these other parties. EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. Description of Business and Basis of Presentation Description of Business Evofem is a San Diego-based commercial-stage biopharmaceutical company committed to commercializing innovative products toaddress unmet needs in women’s sexual and reproductive health. The Company’s first commercial product, PHEXX®, was approved by the FDA on May 22, 2020, for the prevention of pregnancy andlaunched in the U.S. in September 2020. PHEXX is the first and only non-hor